The Administrative Component is responsible for coordinating Pilot &Feasibility Projects, Scientific Core Facilities, Enrichment, and all other activities of the P30 Center. Drs. Sorscher, Kirk and the Business Officer (Ms. Diane Baer) oversee day-to-day administrative operations, and arrange for planning, evaluation, and peer review. The objective of the Administrative Core is to provide effective and integrated processes for our CF Research Base.
Specific Aims are as follows:
Specific Aim 1. To assure smooth and coordinated operation of all P30 components. This includes ongoing assessment of the most effective ways to best serve CF investigators participating in the Center.
Specific Aim 2. To carry out P30 administrative responsibilities set forth by NIH and the University of Alabama at Birmingham. This includes budgeting, monitoring, assessment and reporting requirements associated with the Center grant. In order to accomplish these objectives, the Administrative Core implements recommendations from both internal and external advisors. P30 leadership and advisory committees assure optimal use of Center resources in a fashion that promotes synergy between P30 Components and among the UAB Research Base.
During the current funding cycle, the Administrative Core has worked diligently to assure efficient operation of the NIH Center. Core leadership is experienced and strongly committed to maintaining a rigorous, collaborative, and multidisciplinary research environment. The Core has provided dedicated leadership in these areas, and is well positioned to continue in this capacity in the future.
|Shei, Ren-Jay; Peabody, Jacelyn E; Rowe, Steven M (2018) Functional Anatomic Imaging of the Airway Surface. Ann Am Thorac Soc 15:S177-S183|
|Clancy, John Paul; Cotton, Calvin U; Donaldson, Scott H et al. (2018) CFTR modulator theratyping: Current status, gaps and future directions. J Cyst Fibros :|
|Plyler, Z E; Birket, S E; Schultz, B D et al. (2018) Non-obstructive vas deferens and epididymis loss in cystic fibrosis rats. Mech Dev :|
|Poore, T Spencer; Virella-Lowell, Isabel; Guimbellot, Jennifer S (2018) Potential pathogenicity of Inquilinus limosus in a pediatric patient with cystic fibrosis. Pediatr Pulmonol 53:E21-E23|
|Heltshe, Sonya L; Rowe, Steven M; Skalland, Michelle et al. (2018) Ivacaftor-treated Patients with Cystic Fibrosis Derive Long-Term Benefit Despite No Short-Term Clinical Improvement. Am J Respir Crit Care Med 197:1483-1486|
|Guimbellot, Jennifer; Solomon, George M; Baines, Arthur et al. (2018) Effectiveness of ivacaftor in cystic fibrosis patients with non-G551D gating mutations. J Cyst Fibros :|
|Cho, Do-Yeon; Lim, Dong-Jin; Mackey, Calvin et al. (2018) Preclinical therapeutic efficacy of the ciprofloxacin-eluting sinus stent for Pseudomonas aeruginosa sinusitis. Int Forum Allergy Rhinol 8:482-489|
|Raju, S Vamsee; Rowe, Steven M (2018) Not simply the lesser of two evils. Am J Physiol Lung Cell Mol Physiol 314:L236-L238|
|Peabody, Jacelyn E; Shei, Ren-Jay; Bermingham, Brent M et al. (2018) Seeing cilia: imaging modalities for ciliary motion and clinical connections. Am J Physiol Lung Cell Mol Physiol 314:L909-L921|
|Davies, Jane C; Moskowitz, Samuel M; Brown, Cynthia et al. (2018) VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles. N Engl J Med 379:1599-1611|
Showing the most recent 10 out of 175 publications